Key result
Endothelin receptor antagonists show potential therapeutic value for heart failure based on experimental evidence.
Design
Review
Authors
Loading...
Supports ETA antagonist trials in HF; should not change practice pending randomized data.
This review outlines the pathophysiological mechanisms of the endothelin system in heart failure, providing a rationale for the investigation of ETA receptor antagonists in this population.
Zolk et al. (2000) conducted a review in Heart failure. Endothelin system and endothelin receptor antagonists was evaluated. The cardiac endothelin system is activated in heart failure, and experimental evidence suggests that endothelin receptor antagonists may be of value in treating patients with heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: